Notice of National Heart, Lung, and Blood Institute (NHLBI) Participation in PA-16-183 "Limited Competition: Rare Diseases Clinical Research Network (RDCRN) Project Supplements for Clinical Trials to Repurpose Drugs in Collaboration with E-Rare Awardees (Admin Supp)"

Notice Number: NOT-HL-16-322

Key Dates
Release Date:  May 24, 2016

Related Announcements
PA-16-183

Issued by
National Heart, Lung, and Blood Institute (NHLBI)

Purpose

The purpose of this Notice is to inform potential applicants that the National Heart, Lung, and Blood Institute (NHLBI) is participating, effective immediately, in PA-16-183 "Limited Competition: Rare Diseases Clinical Research Network (RDCRN) Project Supplements for Clinical Trials to Repurpose Drugs in Collaboration with E-Rare Awardees (Admin Supp)".

The following sections of PA-16-183 have been updated to reflect NHLBI's participation in this funding opportunity announcement.    

Part 1.  Overview Information

Components of Participating Organizations
National Heart, Lung, and Blood Institute (NHLBI)
National Center for Advancing Translational Sciences (NCATS)
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Catalog of Federal Domestic Assistance (CFDA) Numbers
93.350, 93.855, 93.856, 93.847, 93.846, 93.837, 93.838, 93.839, 93.233, 93.840

All other aspects of this FOA remain unchanged. 

Inquiries

Please direct all inquiries to:

Lora Reineck, M.D.
National Heart, Lung, and Blood Institute (NHLBI)
Telephone: (301) 435-0222
Email:  lora.reineck@nih.gov